Dr. Arjun Iyengar, M.D
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 34
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 277313 -
Hematology & Oncology Physician
NJ license 25MA09554400 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cooperman Barnabas Medical Center Livingston, NJ
- Newark Beth Israel Medical Center Newark, NJ
- Carepoint Health - Bayonne Medical Center Bayonne, NJ
Medical groups
- Iyengar Hematology Oncology Medical Center PA (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 34
- Services billed
- 7,715
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 133 | 14 |
| Insertion of needle into vein for collection of blood sample | 91 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 59 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Retacrit (epoetin alfa-epbx) | 115 |
| Fosaprepitant Dimeglumine | 80 |
| Eliquis (apixaban) Other prescribers in New York, NY | 66 |
| Letrozole Other prescribers in New York, NY | 61 |
| Neulasta (pegfilgrastim) | 56 |
| Prednisone Other prescribers in New York, NY | 56 |
| Anastrozole Other prescribers in New York, NY | 55 |
| Bortezomib | 52 |
| Abiraterone Acetate | 50 |
| Amlodipine Besylate Other prescribers in New York, NY | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 79 payments worth $1,307 in total to this clinician.
| Janssen Biotech, Inc. | $331 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $183 |
| Exelixis Inc. | $138 |
| Pfizer Inc. | $70.36 |
| AbbVie Inc. | $68.23 |
| GlaxoSmithKline, LLC. | $62.72 |
| Merck Sharp & Dohme LLC | $55.51 |
| Novartis Pharmaceuticals Corporation | $55.01 |
| Food and Beverage | $1,124 |
|---|---|
| Education | $183 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Oct 18, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $92.99 |
| Exelixis Inc. Jan 8, 2025 | Education in-kind | $89.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $146,368 in research payments for these studies, mostly to the institutions running them.
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05100862
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.